



(11) **EP 3 912 642 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:

Corrected version no 1 (W1 A1)
Corrections, see
Bibliography
Remarks

(51) Int Cl.:

A61K 47/68 ^(2017.01) **A61P 15/00** ^(2006.01)
A61P 35/00 ^(2006.01)

(48) Corrigendum issued on:

05.01.2022 Bulletin 2022/01

(43) Date of publication:

24.11.2021 Bulletin 2021/47

(21) Application number: **21171679.0**

(22) Date of filing: **23.10.2013**

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **23.10.2012 EP 12189604**

23.10.2012 US 201261717187 P

14.10.2013 EP 13188607

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

17201445.8 / 3 335 733

13786322.1 / 2 911 699

(71) Applicant: **Synaffix B.V.**

5349 AB Oss (NL)

(72) Inventors:

- **van Delft, Floris Louis**
6524 KZ Nijmegen (NL)
- **van Geel, Remon**
5396 CM Lithoijen (NL)
- **Wijdeven, Maria Antonia**
6603 AH Wijchen (NL)

(74) Representative: **Nederlandsch Octrooibureau**

P.O. Box 29720

2502 LS The Hague (NL)

Remarks:


- This application was filed on 30.04.2021 as a divisional application to the application mentioned under INID code 62.
- Amended claims in accordance with Rule 137(2) EPC.

(54) **MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF**

(57) The present invention relates to an antibody comprising a GlcNAc-S(A)_x substituent, wherein S(A)_x is a sugar derivative comprising x functional groups A wherein A is independently selected from the group consisting of an azido group, a keto group and an alkynyl group and x is 1, 2, 3 or 4, wherein said GlcNAc-S(A)_x substituent is bonded to the antibody via C1 of the N-acetylglucosamine of said GlcNAc-S(A)_x substituent, and wherein said N-acetylglucosamine is optionally fucosylated.

The invention also relates to an antibody-conjugate, in particular to an antibody-conjugate according to the Formula (20) or (20b), wherein AB is an antibody, S is a sugar or a sugar derivative, D is a molecule of interest, and wherein said N-acetylglucosamine is optionally fucosylated (b is 0 or 1).

EP 3 912 642 A8



The invention further relates to a process for the preparation of a modified antibody, to a process for the preparation of an antibody-conjugate, and to said antibody-conjugate for use as a medicament.

In addition, the invention relates to a kit of parts comprising an azide-modified antibody and a linker-conjugate, wherein said linker-conjugate comprises a (hetero)cycloalkynyl group and one or more molecules of interest.

Fig. 4

